Travere Therapeutics Inc (TVTX) Stock Analysis
Verdict: BUY
FILSPARI's rapid IgAN/FSGS commercial ramp drives profitability, but debt obligations and valuation near consensus cap near-term upside.
Investment score: 65/100
Analysis as of
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 70/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
Travere Therapeutics Inc opportunities and risks
What speaks for TVTX
- FILSPARI label expansion into FSGS expands addressable patient pool
What speaks against TVTX
- REMS drug safety monitoring and commercial execution friction
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| TVTX | n/a | 10.2x | 4217.4x | 94.4% | -7.4% | 0.9% |
| RYTM | n/a | 28.7x | n/a | 89.0% | -85.6% | -2.2% |
| CGON | n/a | 1072.8x | n/a | -82.7% | -3602.7% | -2.7% |
| MIRM | n/a | 9.8x | n/a | 81.7% | -139.2% | -7.6% |
| ORKA | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.7% |
| SRRK | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.0% |
| Peer median | n/a | 9.8x | n/a | 0.0% | -85.6% | -2.7% |
Frequently asked questions about Travere Therapeutics Inc (TVTX)
Is TVTX stock a good investment?
The TradeMates model rates Travere Therapeutics Inc as BUY with an investment score of 65/100. FILSPARI's rapid IgAN/FSGS commercial ramp drives profitability, but debt obligations and valuation near consensus cap near-term upside. This is algorithmic model output, not personal investment advice.
Is TVTX stock a buy?
The TradeMates model verdict for TVTX is BUY with an investment score of 65/100. Treat this as a model signal to review, not a personal buy recommendation.